Catalogue of all regulatory announcements and official press releases
29 Jun 2024 Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
28 Jun 2024 Laurus Labs Q1 Trading Window Closure 2024-25
06 Jun 2024 Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulationd, 2011
28 May 2024 Allotment of Equity Shares on exercise of ESOPs
25 Apr 2024 Outcome of the Board Meeting – April 25, 2024
25 Apr 2024 Approval of audited Financial Results for the Year ended March 31, 2024 and Limited Reviewed Financial Results for the Quarter ended March 31, 2024
25 Apr 2024 Intimation of Book Closure pursuant to Regulation 42 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
25 Apr 2024 Corporate Action - 02nd Interim Dividend for FY 2023-24
25 Apr 2024 Laurus Labs Financial Results Q4 FY 2024 Press Release
19 Apr 2024 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
18 Apr 2024 Board Meeting Intimation
18 Apr 2024 Q4 & FY 24 Earnings conference call invite
13 Apr 2024 Incorporation of a Joint Venture Company in India
30 Mar 2024 Laurus Labs Q4 Trading Window Closure 2023-24
17 Feb 2024 Update on Investment in M/s. Immunoadoptive Cell Therapy Private Limited
17 Feb 2024 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
25 Jan 2024 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
23 Jan 2024 Grant of Stock Options to the eligible employees
27 Dec 2023 Closure of Trading Window
12 Dec 2023 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
08 Dec 2023 Allotment of Equity Shares on exercise of ESOPs
21 Nov 2023 Update on acquisition of shares of Laurus Bio Private Limited
20 Oct 2023 Mrs. Sreelakshmi Form C
20 Oct 2023 Change in Directorate
20 Oct 2023 Outcome of the Board Meeting – October 20, 2023
20 Oct 2023 Corporate Action – Interim Dividend for FY 2023-24
16 Oct 2023 Update on acquisition of shares of Laurus Bio Private Limited
13 Oct 2023 Disclosure under Regulation 30 - ImmunoACT announces the approval of India’s first CAR-T cell therapy, NexCAR19 (Actalycabtagene autoleucel), for the treatment of r/r B-cell lymphomas and leukemia from the Central Drugs Standard Control Organization (CDSCO)
29 Sep 2023 Laurus Labs Q2 Trading Window Closure 2023-24
11 Sep 2023 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
11 Sep 2023 Outcome of the Board Meeting dated September 11, 2023
21 Jul 2023 Q1 FY 24 Earnings conference call invite
20 Jul 2023 Laurus Labs Limited Board Meeting On July 27, 2023
15 Jul 2023 Disclosure of Voting Results along with the Scrutinizer Report with respect to the 18th Annual General Meeting held on July 14, 2023
14 Jul 2023 Proceedings of 18th Annual General Meeting
12 Jul 2023 Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 dated May 31, 2023
29 Jun 2023 Update on Credit Rating – Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
26 Jun 2023 Update on Credit Rating – Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
20 Jun 2023 Intimation of Schedule of Analyst/ Institutional Investor Meetings pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations 2015
16 Jun 2023 Newspaper Advertisement
15 Jun 2023 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
31 May 2023 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
30 May 2023 Intimation of Schedule of Analyst/ Institutional Investor Meetings pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations 2015
20 May 2023 Investors Group Meeting May 20, 2023
27 Apr 2023 Corporate Action Agm 2023
27 Apr 2023 Corporate Action 02nd Interim Dividend For FY 2022-23
21 Apr 2023 Laurus Labs Q4 Full Year FY23 result con call invite
19 Apr 2023 Laurus Labs Limited Board Meeting April 27, 2023
31 Mar 2023 Laurus Labs Q4 Trading Window Closure
13 Mar 2023 Investors Group Meeting March 13, 2023
10 Mar 2023 Postal ballot e-voting Results and Scrutinizer Report
10 Feb 2023 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
06 Feb 2023 Antique Conference
30 Jan 2023 Postal Ballot Notice to Stock Exchanges
30 Jan 2023 Postal Ballot Notice dated January 30,2023
30 Jan 2023 Outcome of the Board Meeting – January 30, 2023
21 Jan 2023 Laurus Labs Limited Board Meeting On January 30, 2023
21 Jan 2023 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
21 Jan 2023 Laurus labs ltd. Q3 & 9m fy23 results conference call on monday, 30th january 2023 at 5.00 p.M. (IST)
31 Dec 2022 Closure of Trading Window
27 Dec 2022 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
17 Dec 2022 Allotment of Equity Shares on exercise of ESOPs
24 Nov 2022 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
03 Nov 2022 Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015
28 Oct 2022 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
21 Oct 2022 Laurus Labs outcome of BM October 21, 2022 Corporate Action
21 Oct 2022 Laurus Labs Outcome Ocotber 21, 2022
13 Oct 2022 Laurus Labs Limited Board Meeting On October 21, 2022
13 Oct 2022 Laurus Labs Q2 & 1H FY 23 result con call invite
29 Sep 2022 Laurus Labs Q2 Trading Window Closure 2022-23
17 Sep 2022 Intimation of Schedule of Analyst/ Institutional Investor Meetings pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations 2015
12 Sep 2022 Intimation of Schedule of Analyst/ Institutional Investor Meetings pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations 2015
22 Aug 2022 Stock Ex Intimation Meeting Aug 24 2022FINAL
21 Jul 2022 Laurus labs ltd. Q1 FY 23 results conference call on thursday, july 28, 2022 at 11:00 am IST
19 Jul 2022 Board Meeting Intimation
30 Jun 2022 Grant of Stock Options to the eligible employees
30 Jun 2022 Proceedings of 17111 Annual General Meeting
30 Jun 2022 Disclosure of Voting Results along with the Scrutinizer Report with respect to the 17th Annual General Meeting held on June 30, 2022
29 Jun 2022 Q1 Trading Window Closure
20 Jun 2022 Intimation of Schedule of Analyst/ Institutional Investor Meetings pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations 2015
13 Jun 2022 Intimation of Schedule of Analyst/ Institutional Investor Meetings pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations 2015
09 Jun 2022 Newspaper Advertisement
02 Jun 2022 Newspaper Advertisement
11 May 2022 Disclosure of Related Party Transactions for the half year ended March 31, 2022
11 May 2022 Annual Secretarial Compliance Report for the year ended March 31, 2022
29 Apr 2022 Laurus Labs Q4 FY 22 Earnings Conference Call
29 Apr 2022 Audio Recording of the Q4 & Full Year FY22 Results conference call hosted on April 29, 2022
28 Apr 2022 Corporate Action -02nd Interim Dividend for FY 2021-22
28 Apr 2022 AGM Book Closure FY 2022
28 Apr 2022 AGM Time Change
28 Apr 2022 Initial Disclosure under SEBI circular SEBI/HO/DDHS/CIRJP/2018/144 dated November 26, 2018
25 Apr 2022 Laurus Labs Ltd. Q4 & Full Year Fy22 Results Conference Call
20 Apr 2022 Board Meeting Intimation
07 Apr 2022 Annual Declaration - SAST Reg 31(4)
30 Mar 2022 Laurus Labs Q4 Trading Window Closure 2021-22
22 Mar 2022 Jayasree Form C - 7686 - Buy
14 Mar 2022 Update on schedule of the Analyst/ Institutional Investor Meetings
11 Mar 2022 Intimation of Schedule of Analyst/ Institutional Investor Meetings
28 Feb 2022 Yamini Form C - 2275 Sale
28 Feb 2022 Madhuri Form C - 10K Purchase
21 Feb 2022 Intimation of Schedule of Analyst/ Institutional Investor Meetings
10 Feb 2022 Disclosure under Regulation 30 of LODR Regulations, 2015, as amended
07 Feb 2022 Intimation of Schedule of Analyst/ Institutional Investor Meetings
21 Jan 2022 LAURUS LABS LTD. Q3 & 9M FY22 RESULTS CONFERENCE CALL ON FRIDAY
19 Jan 2022 Laurus Labs Limited Board Meeting On January 27, 2022
30 Dec 2021 Laurus Labs Q3 Trading Window Closure 2021-22
20 Dec 2021 Allotment of Equity Shares on exercise of ESOPs
15 Dec 2021 Chandra kumari Form C 10245 pledg Dec -15,2021
09 Dec 2021 Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 dated November 19,2021
19 Nov 2021 Disclosure of Related Partv Transactions for the half vear ended September 30, 2021
19 Nov 2021 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
17 Nov 2021 SEBI SAST Regulation 29(2) Mrs. Nagarani
17 Nov 2021 SEBI SAST Regulation 29(2) Dr. Satya
17 Nov 2021 NSN Holdings disclosure 29(1) Part-A
15 Nov 2021 NSN Holdings - Disclosure under Reg 10(6) of SAST
08 Nov 2021 NSN Holdings - Disclosure under Reg 10(5) of SAST
28 Oct 2021 Corporate Action - Interim Dividend for FY 2021-22
28 Oct 2021 Outcome of the Board Meeting - October 28, 2021
21 Oct 2021 Laurus Labs Q2 FY 22 result con call invite
20 Oct 2021 Laurus Labs Limited Board Meeting On October 28, 2021
30 Sep 2021 Laurus Labs Q2 Trading Window Closure
17 Sep 2021 Vijaya Kumari Form C 12K Sale
17 Sep 2021 Intimation of Schedule of Analyst/ Institutional Investor Meetings
13 Sep 2021 Intimation of Schedule of Analyst/ Institutional Investor Meetings
07 Sep 2021 Srilakshmi Form C 5000 Sale
02 Sep 2021 AYalamanchi Rama Form C 5500 Sale
13 Aug 2021 Anil Form C 3000 Sale
11 Aug 2021 SS Rao Form C 85777 Sale
11 Aug 2021 Srinivasa Rao S Form C 20000 Sale
10 Aug 2021 Madhuveer Form C 1445 Sale
26 Jul 2021 Laurus Labs Q1 FY 22 results con call invite
19 Jul 2021 Laurus Labs Q1 FY 21-22 Board Meeting July 29, 2021
16 Jul 2021 Disclosure of Voting Results along with the Scrutinizer Report with respect to the 16th Annual General Meeting held on July 15, 2021
15 Jul 2021 Proceedings of 16th Annual General Meeting
07 Jul 2021 Girish Kotapalli Form C 15000 Sale
07 Jul 2021 Narasimha Form C PC and Buy
02 Jul 2021 Venkateswara Rao K Form C 20K PR
01 Jul 2021 Kranthi Form C 1750 Sale
01 Jul 2021 Phanindra Form C 3825 Sale
01 Jul 2021 Narendra Dev Form C 966 Sale
01 Jul 2021 PK Nandi Form C 30K Sale
01 Jul 2021 Sreelakshmi Form C 8000 Sale
01 Jul 2021 Som Parkash Form C 15000 Sale
01 Jul 2021 Satish Kommineni Form C 4000 Sale
01 Jul 2021 Sandhya Rani Form C 2100 Sale
01 Jul 2021 Mohana Form C 5000 Sale
01 Jul 2021 Prathima Chava Form C 1.45 L Sale
30 Jun 2021 Surendra Nath Form C PR and Sale
30 Jun 2021 Jagan Mohana Rao Koya Form C 45K PR and Sale
30 Jun 2021 Closure of Trading Window
29 Jun 2021 Prasad PKV Form C - 65K PC
29 Jun 2021 Giridhar Form C - 65K PC
29 Jun 2021 Murali Mohan P Form C - 35k PC
28 Jun 2021 SS Rao Form C - 2.2L PC
28 Jun 2021 Srinivas Simhadri Form C 13000 Sale
28 Jun 2021 Sita Ramaiah Form C - 35000 Sale
28 Jun 2021 GV Reddy Form C - 2000 Sale
25 Jun 2021 Radha Krishna Form C - 37500 PR
25 Jun 2021 Ratna Kumari Form C - 17500 PR
24 Jun 2021 Ravindra Aduri Form C 15000 Pledge
24 Jun 2021 Naveen Kumar Form C 5000 Sale
24 Jun 2021 Nagi Reddy Form C 2470 Sale
24 Jun 2021 Upgradation in Credit Rating- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
22 Jun 2021 VRN Chowdary Form C 20K Pledge
22 Jun 2021 Venkata Subbarao Form C 900 Sale
22 Jun 2021 Pavan Kumar J Form C 8.5K Pledge
22 Jun 2021 AGM Advertisement
18 Jun 2021 Srinivasa Rao Buddi Form C 2457 Buy
15 Jun 2021 Pavan Elisett -Form C 3465 Sale
15 Jun 2021 Mohana Bikkani Form C 849 Sale
15 Jun 2021 Loka Nagabushan Rao Form C 2375 Sale
14 Jun 2021 Dr. Lakshman Form C 17L Pledge Release
11 Jun 2021 Suneetha Nair Form C 5665 Sale
10 Jun 2021 Venkata Subbarao Form C 3000 Sale
10 Jun 2021 JN Rao Form C 5000 Sale
10 Jun 2021 Ravi Kumar V V Form C 4L Sale
09 Jun 2021 Dr. Lakshman Rao C V Form C 4L Sale
09 Jun 2021 Jagan Mohana Rao K Form C 25000 Sale
09 Jun 2021 GV Reddy Form C 3000 Sale
09 Jun 2021 Dr. Samatha Form C 1700 Sale
09 Jun 2021 Narendra Babu T Form C 2810 Sale
09 Jun 2021 Narendra Dev V Form C 2200 Sale
09 Jun 2021 Babchand Form C 10000 Sale
09 Jun 2021 Babchand Form C 20000 Sale
08 Jun 2021 Sumanth K Form C 2700 Sale
07 Jun 2021 Babchand N Form C 10000 Sale
07 Jun 2021 Pre AGM Notice FY 2020-21
03 Jun 2021 Babchand Form C 10000 Sale
02 Jun 2021 D MVG Rao Form C 2600 Buy
02 jun 2021 Dr. Ravindra Aduri Form C 4376 Sale
01 Jun 2021 VNVPRASAD Form C 17000 Pledge
31 May 2021 Amarchand Form C 3750 Sale
31 May 2021 Madhuveer Form C 2000 Sale
28 May 2021 Tejavathi Form C 3810 Sale
28 May 2021 Mohana Form C 2151 Sale
28 May 2021 Babchand Form C 10000 Sale
26 May 2021 Mani Bushan K Form C 10000 Sale
25 May 2021 Narendra Dev Form C 4500 Sale
24 May 2021 Veeraiah Form C 5000 Sale
21 May 2021 Sridhar Shyam Form C 4300 Sale
21 May 2021 Satish Form C 8139 Buy
18 May 2021 Intimation of Schedule of Analyst/ Institutional Investor Meetings
13 May 2021 Meher Form C 5400 Sale
13 May 2021 Ravi Varma Form C 8160 Pledge
12 May 2021 Veeraiah Form C 3510 Sale
11 May 2021 Pavan E Form C 8418 Sale
11 May 2021 Rajesh Nallani Form C 6440 Pledge
11 May 2021 Murali Apparaju Form C 11000 Sale
05 May 2021 Suresh Form C 9100 - Sale
05 May 2021 GVR Form C 5500 - Sale
04 May 2021 Jagan Form C Sale - 75500
04 May 2021 Navneet Mehta Form C Sale - 10000
04 May 2021 Srinivas Form C 3000 - Sale
29 Apr 2021 Disclosure for a Large Corporate Entity
29 Apr 2021 Intimation of Book Closure pursuant to Regulation 42 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
29 Apr 2021 Corporate Action -3rd Interim Dividend for FY 2020-21
29 Apr 2021 Grant of Stock Options to the eligible employees
29 Apr 2021 Outcome of the Board Meeting - Apri129, 2021
26 Apr 2021 Laurus Labs Ltd. Q4 & Fy21 Results Conference Call On Friday, April 30, 2021 At 11:00 Am IST
22 Apr 2021 Board Meeting Intimation
01 Apr 2021 Form C Mr. Sunder
30 Mar 2021 Laurus labs Q4 Trading Window Closure
23 Mar 2021 Revision in Credit Rating - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
18 Mar 2021 Form C Chandra Kumari
12 Mar 2021 Form C Mr. Satish
12 Mar 2021 SEBI-SAST-Regulation 31(1)(2)-5750000 - Dr. Satya Pledge Release Bajaj Finance
12 Mar 2021 SEBI-SAST Regulation 31(2)(2)-5750000 - Dr. Satya Pledge Release Tata Capital
12 Mar 2021 SEBI-SAST Regulation 31(1)(2)-6575000 - Dr. Satya Pledge Release AXIS FINANCE
12 Mar 2021 SEBI-SAST Regulation 31(2)(2)-800000 - Dr. Lakshma Pledge Release Adity
12 Mar 2021 Form C Pledge Release Dr. Satya
12 Mar 2021 Form C Pledge Release Dr. Lakshman
11 Mar 2021 Form C Mrs. Nagarani Chava Pledge Release 3750000
12 Mar 2021 SEBI-SAST Regulation 31(1)(2)-3750000 - Mrs. Nagarani Pledge Release AXIS FINANCE
09 Mar 2021 Form C Krishna Kishore JVV
09 Mar 2021 Form C Dr. Ravindra Aduri
08 Mar 2021 Form C Mr. Vijay Krosuri
08 Mar 2021 Form C Mr. DVL Narasimha Rao
04 Mar 2021 Form C Mr. Madhusudan Reddy
04 Mar 2021 Form C 18L S Mrs. Nagarani
04 Mar 2021 Form C 52L S Dr. Satya
17 Feb 2021 Analyst Investor Meetings
16 Feb 2021 Form C Ravikrishna Chebolu
10 Feb 2021 Update on Acquisition of stake in Richcore Lifesciences Private Limited
09 Feb 2021 Form C Mrs. Mahalakshmi M
09 Feb 2021 Form C Dr. MVG Rao
06 Feb 2021 Form C Mrs. Mahalakshmi Malempati
06 Feb 2021 Form C Dr. MVG Rao
04 Feb 2021 Form C Dr. MVG Rao
03 Feb 2021 Form C Mr. PKVPrasad
03 Feb 2021 Form C Mr. Satish
03 Feb 2021 Form C Mr. Babchand N
02 Feb 2021 Intimation of Schedule of Analyst/ Institutional Investor Meetings
01 Feb 2021 Form C Mr. Krishna Kishore JVV
28 Jan 2021 Outcome of the Board Meeting - January 28, 2021
28 Jan 2021 Corporate Action -2nd Interim Dividend for FY 2020-21
20 Jan 2021 Update on Acquisition of stake in Rich core Lifesciences Private Limited
19 Jan 2021 Laurus Labs Limited Board Meeting On 28.01.2021
11 Jan 2021 Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 - incorporation of Step-Down Subsidiary
02 Jan 2021 Form C Dr. Uttam
31 Dec 2020 Form C M. Giridhar
31 Dec 2020 Form C Dr. Samatha
30 Dec 2020 Laurus Labs Q3 Trading Window Closure
29 Dec 2020 Form C Mr. Sridhar Shyam
28 Dec 2020 Mr and Mrs. Satyanarayana Tinnaluri Form C
22 Dec 2020 Form C ESOPS
22 Dec 2020 Allotment of Equity Shares on exercise of ESOPs
18 Dec 2020 Form C Smt. Sarada Kurapati
10 Dec 2020 Form C Dr Satya
09 Dec 2020 SEBI-SAST Regulation 31(1)(2)-2200000-Dr. Satya-Pledge Release - AXIS FINANCE
09 Dec 2020 SEBI-SAST Regulation 31(1)(2)-1100000 Dr. Satya-Pledge Release - AXIS FINANCE
09 Dec 2020 SEBI-SAST Regulation 31(1)(2)-1100000 Dr. Satya-Pledge Creation - AXIS FINANCE
09 Dec 2020 SEBI-SAST Regulation 31(1)(2)-1750000 Dr. Satya-Pledge Release - TATA CAPITAL
09 Dec 2020 Form C Dr Satya
08 Dec 2020 Intimation of Schedule of Analyst/ Institutional Investor Meetings
07 Dec 2020 Form C Mr. PKV Prasad
04 Dec 2020 Form C Naveen Kumar V
02 Dec 2020 Intimation of Schedule of Analyst/ Institutional Investor Meetings
02 Dec 2020 Form C Dr. Vaidyanathan Iyer Narayana Swamy
26 Nov 2020 Conference Call of Laurus Labs Ltd’s Acquisition of Richcore Lifesciences Pvt. Ltd.
25 Nov 2020 Investors/ Analysts Presentation
25 Nov 2020 Laurus Labs Ltd. Acquires Majority Stake In Richcore Lifesciences Conference Call On Thursday
25 Nov 2020 Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
23 Nov 2020 Form C Mr. Jagan Mohan
23 Nov 2020 Intimation of Schedule of Analyst/ Institutional Investor Meetings
19 Nov 2020 Intimation of Schedule of Analyst/ Institutional Investor Meetings
19 Nov 2020 Form C S srinivasaRao
19 Nov 2020 Form C Mr. Chandrakanth
13 Nov 2020 Form C Mr. Pavan Kumar Nerella
12 Nov 2020 Form C Mr. Pavan Kumar Nerella
11 Nov 2020 Form C Mr. Murali Krishna
11 Nov 2020 Form C Mr. Chandrakanth
10 Nov 2020 Form C Mr. Krishna Chaitanaya
09 Nov 2020 Form C Mr. Harikrishna K
09 Nov 2020 Form C Mr. Sita Ramaiah
07 Nov 2020 Form C Mr. Chandrakanth
04 Nov 2020 Form C Ms. Soumya
04 Nov 2020 Form C Mr. Chandrakanth
29 Oct 2020 Laurus Labs Corporate Action -Interim Dividend for FY 2020-21
29 Oct 2020 Laurus Labs Approval Letter for reclassification of Shareholding from Promoter Category to Public Category
29 Oct 2020 Laurus Labs Outcome of the Board Meeting 29.10.2020
26 Oct 2020 LAURUS LABS LTD Q2 & H1 FY21 results conference call
19 Oct 2020 Laurus Labs Limited Board Meeting On 29.10.2020
01 Oct 2020 Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Merger of two foreign subsidiaries of the Company
29 Sep 2020 Form C Ms. Rochana Devi R
29 Sep 2020 Closure of Trading Window
28 Sep 2020 Intimation of Schedule of Analyst/ Institutional Investor Meetings
28 Sep 2020 From C Ms. Deepthi
25 Sep 2020 Form C Mr. CNR
23 Sep 2020 From C Dr. Radha Krishna S Spouse PLedge
23 Sep 2020 From C Dr. Radha Krishna S Spouse BUY
22 Sep 2020 Form C Narendra Kumar K
22 Sep 2020 Form C dated 22.09.2020 Dr. Satya Pledge Release
22 Sep 2020 Form C dated 22.09.2020 Mrs. Nagarani Pledge Release
22 Sep 2020 SEBI SAST Regulation 31(1)(2)-225000 Dr. Satya Pledge Release AXIS
22 Sep 2020 SEBI SAST Regulation 31(1)(2)-750000 Mrs. Nagarani Pledge Release AXIS
21 Sep 2020 From C Mr. Tirumal Reddy
21 Sep 2020 Form C Mr. Srinivasa Rao Suryadevara
21 Sep 2020 Form C Dr. Uttam
16 Sep 2020 Form C dated16.09.2020 Dr. Satya Pledge Release
16 Sep 2020 SEBI SAST Regulation 31(1)(2) - 650000 Dr. Satya Pledge Release
16 Sep 2020 From C Dr. Radha Krishna S Spouse
12 Sep 2020 From C Dr. Radha Krishna S
10 Sep 2020 Form C Dr. Lakshman Rao CV
10 Sep 2020 Form C Mr. Satyanarayana Goud K GV Reddy Form C - 2000 Sale
08 Sep 2020 Form C Mr. Babchand 08.09.2020 Pledge Release
07 Sep 2020 Form C Mudit Singhal
04 Sep 2020 Form C Mr. Babchand
03 Sep 2020 Form C Mrs. S. Rama
02 Sep 2020 Form C Mr. Sita Ramaiah
02 Sep 2020 Form C Mr. Ramakrishna BV
02 Sep 2020 Intimation of Schedule of Analyst/ Institutional Investor Meetings
28 Aug 2020 Form C Ms. Vamsi Rekha
27 Aug 2020 Form C Mr. Rajesh Nallani
18 Aug 2020 Intimation of Schedule of Analyst/ Institutional Investor Meetings
18 Aug 2020 Form C Mr. Ramakrishna Rao K
18 Aug 2020 Form C Ms. Santhi Wo Dr. UMA
17 Aug 2020 From C Dr. MVG Rao
12 Aug 2020 Form C dated 12.08.2020 Dr. Satya Pledge Release and Creation
12 Aug 2020 SEBI SAST Regulation 31(1)(2) - 1500000 Dr. Satya Pledge Creation - TATA
12 Aug 2020 SEBI SAST Regulation 31(1)(2) - 500000 Dr. Satya Pledge Release - BAJAJ
12 Aug 2020 SEBI SAST Regulation 31(1)(2) - 1560000 Dr. Satya Pledge Release - AXIS
10 Aug 2020 Form C Mr. Murali Apparaju
10 Aug 2020 Form C Mr. Suresh Babu M
10 Aug 2020 Form C Mudit Singhal
08 Aug 2020 Form C Mr. P K Nandi
30 Jul 2020 Laurus Labs Outcome of the Board Meeting
30 Jul 2020 Laurus Labs Split Corporate Action
29 Jul 2020 SEBI SAST Regulation 31(1)(2)-2500000 Dr. Satya
29 Jul 2020 Form C dated 29.07.2020 Dr. Satya
27 Jul 2020 Laurus Labs Investor Call
24 Jul 2020 SEBI SAST Dr. SATYA
24 Jul 2020 Form C 24.07.2020
21 Jul 2020 Laurus Labs Board Meeting Intimation Q12020-21
20 Jul 2020 Laurus Labs Application to Stock Exchanges for Reclassification
17 Jul 2020 Form C ESOP
16 Jul 2020 Laurus Labs ESOP Allotment JULY 2020
14 Jul 2020 Form C Mr. Vijay Prakash
11 Jul 2020 Evoting Results 15th AGM
10 Jul 2020 Report on Voting Results of 15th Annual General Meeting
09 Jul 2020 Proceedings of 15th Annual General Meeting
09 Jul 2020 Reclassification of Promoter Category of Dr.Raju
04 Jul 2020 Laurus Labs Update on Acquisition NAME CHANGE
01 Jul 2020 Laurus Labs Addendum to AGM Notice 2020
01 Jul 2020 Laurus Labs Update on Acquisition
01 Jul 2020 Laurus Labs Mr. Narendra Ostawal Resignation
01 Jul 2020 Disclosure Reg 29(2)-Bluewater Investment
30 Jun 2020 SEBI-SAST Regulation 31(1)(2)-2500000-Dr Satya-Pledge Release
30 Jun 2020 SEBI-SAST Regulation 31(1)(2)-2500000-Dr Satya-Pledge Creation
30 Jun 2020 Form C Mr. Chandrakanth
30 Jun 2020 Form C dated 30.06.2020 Mr. CNR
30 Jun 2020 Form C dated 30.06.2020 Dr. Satya-Pledge Release
30 Jun 2020 Form C dated 30.06.2020 Dr. Satya-Pledge Creation
30 Jun 2020 Laurus Labs Q1 Trading Window Closure 2020-21
26 Jun 2020 Form C Dr. Lakshman
26 Jun 2020 Form C Mr. Jagan
25 Jun 2020 Form C Mr. Jagan
25 Jun 2020 Form C Mr. Chandrakanth
18 Jun 2020 SAST Declaration Dr. Satyanarayana C
18 Jun 2020 SAST Declaration Mrs. Nagarani
18 Jun 2020 Form C Mrs. Nagarani
18 Jun 2020 Form C Dr. Satyanarayana C
15 Jun 2020 Laurus Labs AGM Notice FY 2019-20
06 Jun 2020 Laurus Labs News paper Advertisement
28 May 2020 Laurus Labs outcome of Board Meeting Corporate Action
27 May 2020 Disclosure to stock exchanges COVID19
27 May 2020 Laurus Labs RPT Disclosure March 2020
14 May 2020 Form C 14.05.2020
12 May 2020 Disclosure Reg 29(2) SEBI (SAST) Reg.2011 ERML
11 May 2020 Disclosure Reg 29(2) SEBI (SAST) Reg.2011
09 May 2020 Form C 09.05.2020
30 Apr 2020 Outcome of Board Meeting 30.04.2020
27 Apr 2020 Laurus Labs Con Call 30.04.2020
24 Apr 2020 Laurus Labs Board Meeting Intimation
06 Apr 2020 Form C 06.05.2020
06 Apr 2020 Declaration Reg 31 SAST 2011-31.03.2020
06 Apr 2020 Disclosure Reg 30 SAST 2011-31.03.2020
31 Mar 2020 Form C dated 31.03.2020
31 Mar 2020 Form C 31.03.2020
31 Mar 2020 SEBI-SAST Regulation 31(1)(2) 2000000
31 Mar 2020 Form C 31.03.2020
31 Mar 2020 SEBI-SAST Regulation 31(1)(2) 250000
31 Mar 2020 Laurus Labs Q4 Trading Window Closure 2019-20
30 Mar 2020 Form C dated 30.03.2020
26 Mar 2020 Form C dated 26.03.2020
20 Mar 2020 Form C dated 25.03.2020
20 Mar 2020 Laurus Labs Furtherance Letter
20 Mar 2020 SEBI SAST REGULATION 31(1)(2) 2750000
20 Mar 2020 Form C 20.03.2020
20 Mar 2020 Form C 20.03.2020
20 Mar 2020 Form C 20.03.2020
18 Mar 2020 Form C 18.03.2020
17 Mar 2020 Form C 17.03.2020
12 Mar 2020 Laurus Labs out come of Board Meeting 12.03.2020
12 Mar 2020 Laurus Labs outcome of Board Meeting Corporate Action 12.03.2020
04 Mar 2020 Laurus Labs Board Meeting On March-12 04.03.2020
29 Feb 2020 Intimation of Resignation of Independent Director of the Company 29.02.2020
21 Feb 2020 Analyst Investor Meet Intimation 21.02.2020
14 Feb 2020 Form C Regulation 7(2) 14.02.2020
11 Feb 2020 Form C 11.02.2020
06 Feb 2020 Form C 06.02.2020
27 Jan 2020 Laurus Labs Con Call invite Q3 2019-20
23 Jan 2020 Laurus Labs Receives EIR from USFDA
31 Dec 2019 Laurus Labs Board Meeting Intimation Q3 2019-20
31 Dec 2019 Form C 31.12.2019
31 Dec 2019 Form C 31.12.2019
31 Dec 2019 Form C 31.12.2019
31 Dec 2019 Form C 31.12.2019
31 Dec 2019 Form C 31.12.2019 Hyderabad
31 Dec 2019 Form C Pledge 31.12.2019
31 Dec 2019 SEBI SAST Regulation 31(1)(2) Dr. Lakshman
31 Dec 2019 Laurus Labs Trading Window Closure Q3
27 Dec 2019 Form C 27.12.2019
26 Dec 2019 Form C 26-12-2019
26 Dec 2019 Letters for Reclassification
24 Dec 2019 Regulation 7(2) - Dr.Raju 24-12-2019
24 Dec 2019 Form C 24-12-2019
23 Dec 2019 Form C 23-12-2019
23 Dec 2019 SEBI-SAST Regulation 31(1)(2)-90000-Dr.Lakshman
18 Dec 2019 Form C 18-12-2019
16 Dec 2019 Laurus Labs ESOP Grants
07 Dec 2019 Change of Name of Share Transfer Agent
27 Nov 2019 Form C 27-11-2019
25 Nov 2019 Form C 25-11-2019
25 Nov 2019 Analyst Investor Meet Intimation
06 Nov 2019 Laurus Labs RPT Disclosure
29 Oct 2019 Laurus Labs Con Call Invite Q2 2019-20 Results
21 Oct 2019 Laurus Labs Board Meeting Intimation 31 10 2019
01 Oct 2019 Form C 01-10-2019
30 Sep 2019 Laurus Labs trading Window Closure Q2
27 Sep 2019 Form C 27-09-2019
26 Oct 2019 Form C - ESOP 2019
24 Sep 2019 Laurus Labs ESOPs Allotment 2019
24 Sep 2019 SEBI-SAST Regulation 31(1)(2)-100000-Dr Lakshman
24 Sep 2019 Form C 24-09-2019
21 Sep 2019 Form C 21-09-2019
19 Sep 2019 Form C 19-09-2019
08 Sep 2019 Laurus Labs Disclosure Reg 30 Acquisition of Foreign entity in South Africa
06 Sep 2019 Form C 06 Sep 2019
21 Aug 2019 Laurus Labs Intimation of Analyst Investor Call
16 Aug 2019 Form C 16 Aug 2019
09 Aug 2019 Form C 09 Aug 2019
30 July 2019 Laurus Labs Q1 FY2020 Results Conference Call
24 July 2019 Board Meeting Intimation
12 July 2019 Proceedings of 14th Annual General Meeting
12 July 2019 Results of Voting- 14th Annual General Meeting
29 June 2019 Disclosure under Reg 30(1) & 30(2) of SAST Reg 2011.
29 June 2019 Closure of Trading Window.
29 June 2019 Disclosure under Regulation 7(2) of SEBI (PIT) Regulations 2015
31 May 2019 Form C 31 May 2019.
31 May 2019 Disclosure on Related Party Transactions.
17 May 2019 Form C.
14 May 2019 Certificate under Regulation 74(5) of the SEBI Regulations 2018.
3 May 2019 Q4 FY19 Conference Call Transcript.
2 May 2019 Intimation of Book Closure pursuant to Regulation 42 of the Securities & Exchange Board of lndia Regulations, 2015.
30 Apr 2019 LAURUS LABS LTD. Q4 & FY19 RESULTS CONFERENCE CALL
30 Apr 2019 Not-applicability of Large Corporate Criteria.
25 Apr 2019 Board Meeting
4 Apr 2019 Closure of Trading Window
2 Apr 2019 Disclosure under Regulation 30 of SEBI Regulations 2011
28 Mar 2019 Disclosure by the promoter(s) to stock exchanges and to the target company for encumbrance of shares
25 Mar 2019 Details of change in holding of Securities of Promoter, Employee or Director of a listed company and other such persons as mentioned in Regulation 6(2)
21 Mar 2019 Intimation of Schedule of Analyst/ Institutional Investor Meetings pursuant to Regulation 30 of Securities and Exchange Board of India Regulations 2015
19 Mar 2019 Details of change in holding of Securities of promoter, Employee or Director of a listed company and other such persons as mentioned in regulation 6(2)
18 Mar 2019 FIL Capital Disclosure
12 Mar 2019 Details of change in holding of Securities of Promoter, Employee of Director of a listed company and other such person as mentioned in Regulation 6(2)
21 Feb 2019 Intimation of Schedule of Analyst/ Institutional Investor' Meetings pursuant to Regulation 30 of Securities and Exchange Board of India Regulations 2015
18 Feb 2019 Disclosure under Regulation 7(2) read with Regulation 6(2) of SEBI (PIT) Regulations 2015
14 Feb 2019 Disclosure under Regulation 7(2) read with Regulation 6(2) of SEBI (PIT) Regulations 2015
1 Feb 2019 Q3 FY19 Conference Call Transcript
1 Feb 2019 Laurus Labs Q3 & 9M FY19 results concall invite
23 Jan 2019 Board Meeting Intimation
2 Jan 2019 LaurusLabs Disclosure under Reg7(2)of SEBI(PIT) Reg 2015 02 Jan 2019
20 Dec 2018 LaurusLabs Granting of Stock Options to The Eligible Employees
15 Dec 2018 LaurusLabs Disclosure under Reg7(2)of SEBI(PIT) Reg 2015 15 Dec, 2018
1 Dec 2018 Transfer of operations of Share Transfer Agent from Karvy Computershare Private Limited to Karvy Fintech Ptivate Limited
27 Nov 2018 Laurus Labs Disclosure under Reg 7(2) of SEBI(PIT) 2015 27 Nov,2018
15 Nov 2018 LaurusLabs Disclosure under Reg7(2) of SEBI(PIT) Reg 2015 15 Oct,2018
2 Nov 2018 Q2 FY19 Conference Call Transcript
10 Nov 2018 Disclosure under Reg 30(1) & 30(2) of SAST Reg 2011 Dr Satya
10 Nov 2018 Disclosure under Reg 30(1) & 30(2) of SAST Reg 2011 Ms Nagarani
8 Nov 2018 Laurus Labs Disclosure under Reg7(2) of SEBI(PIT) Reg2015 08 Oct, 2018
3 July 2018 Disclsoure under Reg7(2) of SEBI(PIT) Regulations 2015
2 Nov 2018 Disclsoure under Reg7(2) of SEBI(PIT) Regulations 2015
2 Nov 2018 Laurus Labs Q2 & H1 FY 19 Results ConCall Invite
26 Oct 2018 Disclsoure under Reg 7(2) of SEBI (PIT) Regulations 2015 - 26 Oct, 2018
23 Oct 2018 Board Meeting Intimation
11 Oct 2018 Disclsoure under Reg7(2) of SEBI (PIT) Regulations 2015 11-10-2018
06 Oct 2018 Disclsoure under Reg7(2) of SEBI(PIT) Regulations 2015 - 06 Oct 2018
28 Sep 2018 Disclsoure under Reg7(2) of SEBI(PIT)Regulations 2015 28-09-2018
25 Sep 2018 Disclsoure under Reg7 (2) of SEBI (PIT) Regulations 2015 25 Sep 2018
24 Sep 2018 Disclsoure under Reg7(2) of SEBI(PIT) Regulations 2015
20 Sep 2018 Laurus Labs Intimation of Allotment of Sharesunder ESOP Schemes
21 Aug 2018 Disclosure under Reg-7(2) readd with Reg-6(2) of PIT Reg2015 21-Aug-2018
14 Aug 2018 SEBI SAST Reg 31 (1) & (2) - 14.08.2018
13 Aug 2018 Disclosure under Reg-7(2) readd with Reg-6(2) of PIT Reg 2015 13 Aug
9 Aug 2018 Disclosure under Reg 7(2) readd with Reg 6(2) of PIT Reg 2015
4 Aug 2018 Laurus Labs Q1 FY19 Conference Call Transcript
4 Aug 2018 Laurus Labs Q1 FY19 Results Conference Call Intimation
26 July 2018 Board Meeting Intimation 3rd August 2018
6 July 2018 Results of Voting 13th Annual General Meeting
6 July 2018 Proceedings of 13th Annual General Meeting
6 July 2018 Disclosure under Reg 7(2) readd with Reg 6(2) of PIT Reg 2015 - July6 2018
29 June 2018 Disclosure under Regulation Regulations 7(2) read with Regulation 6(2) of SEBI (PIT) 2015
7 June 2018 Disclosure under Regulation Regulations 7(2) read with Regulation 6(2) of SEBI (PIT) 2015 (June 7, 2018)
6 June 2018 SEBI SAST Reg 31 of (1) (2) 6240000
5 June 2018 Disclosure under Regulation 7(2) read with Regulation 6(2) of SEBI (PIT) Regulations 2015
4 June 2018 Intimation of Schedule of Analyst/ Institutional Investor Meetings pursuant to Regulation 30 of Securities and Exchange Board of India Regulations 2015
30 May 2018 SEBI-SAST Reg 31 of (1) (2) - 2790000
31 May 2018 Disclosure under Regulation 7(2) read with Regulation 6(2) of SEBI (PIT) Regulations 2015
30 May 2018 Disclosure under Regulation 7(2) read with Regulation 6(2) of SEBI (PIT) Regulations 2015
29 May 2018 Disclosure under Regulation 7(2) read with Regulation 6(2) of SEBI (PIT) Regulations 2015
11 May 2018 Laurus Labs Q4 FY18 Conference Call Transcriptn
10 May 2018 Outcome of Board Meeting (May 10,2018)
10 May 2018 Laurus Labs Q4 FY18 Results Conference Call Invitation May 11 2018
10 May 2018 Board Meeting Intimation 10th May 2018
10 April 2018 Reporting under Regulation 29(1)of SEBI-SBI Mutual Funds 10-04-2018
05 April 2018 Disclosure Under Reg(30) of SEBI(SAST)Regulations 2011
31 March 2018 Disclosure under Reg 7(2) of SEBI(PIT) Regulations 2015
8 March 2018 Change in Directorate Appointment of Dr Lakshmana Rao CV
8 March 2018 Resignation of Dr. Srihari Raju Kalidindi
28 February 2018 Analyst - Investor - Meet Intimation 28-02-2018
30 January 2018 Conference Call Transcript Jan 30, 2018
30 January 2018 Laurus Labs Q3 9M FY18 Results Conference Call Invitation (Jan 30, 5 PM)
19 January 2018 Board Meeting Intimation 29th January 2018
26 December 2017 Disclosure under Reg 7(2) of SEBI (PIT) Regulations 2015 Mr.S.Sathyanarayana 26-12-2017
21 December 2017 Disclosure under Reg 7(2) of SEBI (PIT) Regulations 2015 Mr.N.Babchand 19-12-2017
4 December 2017 Analyst - Investor - Meet - Intimation 04-12-2017
30 November 2017 Laurus Labs receives maiden Tentative Approval from USFDA for Tenofovir Disoproxil Fumarate Tablets
24 November 2017 Resignation of Mr. Rajesh Kumar Dugar, Director of Laurus Labs
10 November 2017 Conference Call Transcript 10-11-2017
14 November 2017 Laurus Labs received the EIR for its Units 1 & 3
1 November 2017 Board Meeting Intimation
18 November 2017 Disclosure under Regulation 7(2) Regulation 6(2) of SEBI(PIT) Regulations 2015
11 October 2017 Analyst Investor Meet – Intimation 12-10-2017
21 September 2017 Allotment of Equity Shares on exercise of ESOPs
15 September 2017 Unit 2 receives EIR from USFDA and completes German Regulatory Authority inspection; WHO inspections completed for Unit 1 & 3
4 September 2017 Intimation of Schedule of Analyst/Institutional Investor Meetings Pursuant to Regulation 30 of Securities and Exchange Board of India Regulations 2015
29 August 2017 Intimation of Schedule of Analyst/ Institutional Investor Meetings on August 29, 2017
4 September 2017 Intimation of Schedule of Analyst/Institutional Investor Meetings Pursuant to Regulation 30 of Securities and Exchange Board of India Regulations 2015
11 August 2017 Q1 & FY 2018 Results: Analyst & Investor Call (Aug 11, 2 PM)
1 August 2017 Intimation of Board Meeting
13 July 2017 Proceedings of AGM 12-07-2017
13 July 2017 AGM Voting Results 12-07-2017
31 May 2017 Intimation of Schedule of Analyst / Institutional Investors Meetings pursuant to Retulation 30 of Securities and Exchange Board of India
19 May 2017 Unit 2 USFDA Audit Successful
18 May 2017 Q4 & FY 2017 Results: Investor Presentation
18 May 2017 Outcome of Board Meeting (May 18)
19 May 2017 Q4 & FY 2017 Results: Analyst & Investor Call (May 19)
9 February 2017 Q3 & FY 2017 Results: Investor Presentation
8 May 2017 Announcement
8 May 2017 Intimation of Board Meeting
8 May 2017 Intimation of Demise of Director
27 March 2017 Resignation of Director - Reg
11 March 2017 Disclosures under Regulation 30 of the SEBI
1 March 2017 Disclosure under Reg 7(2) of SEBI (PIT) Regulations 2015 01-03-2017
10 February 2017 Intimation of Conference Call
2 February 2017 Board meeting Intimation for Results & Closure of Trading Window
2 January 2017 Resignation of Director-Conner Town Mulvee
29 December 2016 Change of CIN - Reg
23 December 2016 Disclosure under Reg 7(2) of SEBI (PIT) Regulations 2015_23-12-2016
20 December 2016 Reporting under Regulation 29(1) of SEBI
25 Jan 2024 Press Release - JV Agreement with KRKA
24 Jan 2024 Press Release - Laurus Labs Financial Results Q3 FY 2024
20 Oct 2023 Press Release - Financial Results Q2 FY 2024
27 Jul 2023 Press Release - Financial Results Q1 FY 2024
22 Jun 2023 Press Release - Newspaper Advertisement
19 Jun 2023 Press Release - Laurus Labs signs Memorandum of Agreement (MOA) with IIT Kanpur for novel gene therapy assets
31 May 2023 Press Release - Laurus Labs further invests in Cell and Gene therapy company ImmunoACT; to hold 33.86% stake post- completion of the transaction
02 May 2023 Press Release - Laurus Labs receives USFDA tentative approval for the World's First Paediatric ARV Oral Dispersible Film (ODF) drug, Dolutegravir 5mg and 10mg in HIV/AIDS treatment
27 Apr 2023 Laurus Labs Financial Results Q4 FY 2023 Press Release
30 Jan 2023 Laurus Labs Financial Results Q3 FY 2023 Press Release
21 Oct 2022 Laurus Labs Financial Results Q2 FY 2023 Press Release
27 Jul 2022 Laurus Labs Financial Results Q1 FY 2023 Press Release
28 Apr 2022 Press Release - Q4 Press Release FY 2022
27 Nov 2021 Press Release - Laurus Labs Financial Results Q3 FY 2022
21 Nov 2021 Press Release - Laurus Labs signs an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication
19 Nov 2021 Press Release titled - Laurus Labs acquires substantial minority stake in a CAR-T cell therapy company - ImmunoACT
28 Oct 2021 Healthy Growth momentum with 17% revenue growth for H1FY22
14 Sep 2021 Press Release - Laurus Labs, Unitaid and the Clinton Health Access Initiative, announce agreement to accelerate development of best-in-class second- and third-line HIV medication for children
29 Jul 2021 Press Release - Laurus Labs Financial Results Q1 FY 2022
02 Jul 2021 Press Release- Laurus Labs receives the License to manufacture and market 2-Deoxy-D-Glucose (2DG) in India, from DRDO
29 Apr 2021 Laurus Labs Financial Results Q4 FY 2021 Press Release
04 Mar 2021 Laurus labs promoters, Dr.Satyanarayana chava, founder and ceo & Mrs. Nagarani chava, promoter, are set to release the pledge of shares of the company
20 Feb 2021 Laurus Labs wins coveted Golden Peacock Award for Excellence in Corporate Governance
28 Jan 2021 Revenue growth of 76% and PAT growth of 274% in Q3 FY21
25 Nov 2020 Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences
29 Oct 2020 Laurus Labs Press Release Board Meeting Oct 29 2020
29 Oct 2020 Q2 H1 FY21 Press Release Oct 29 2020
30 Jul 2020 Press Release - Strong Revenue growth of 77% and PAT growth of 1047%
19 May 2020 Press Release - Laurus Labs receives USFDA approvals for ANDAs TLE 400 and TLE 600 tablets.
30 Apr 2020 Press Release - Highest Ever Profit after Tax at INR 2,553 mn in FY20, growth of 172%
27 Mar 2020 Rising Pharmaceuticals and Laurus Labs Partner to Support the University of Minnesota to Explore the Prophylaxis Effect of Hydroxychloroquine in Essential Health Care Workers
26 Mar 2020 Laurus Labs donates Hydroxychloroquine (HCQ) IP 200mg tablets & INR 50 lakhs fund to fight the COVID-19 pandemic in Telangana and Andhra Pradesh States
30 Jan 2020 Press Release - PROFIT AFTER TAX AT INR 73.5 crs in Q3 FY20 with a growth of 313 %
21 Nov 2019 Laurus Labs completes US FDA, pre-approval inspection (P AI), for an API manufactured at its units 1&3, Visakhapatnam
08 Nov 2019 Laurus Labs completed the USFDA Inspection of its FDF & API Integrated Facility, Unit 2, at Visakhapatnam
30 Oct 2019 Laurus Labs Financial Results Q2 FY 2020 Press Release
18 Sep 2019 Laurus Labs to acquire the Subsidiary Company of Aspen Pharmacare, South Africa
05 Sep 2019 Laurus Labs receives an EIR from USFDA for its API Units 1 & 3 and also received an ERP approval for fixed dose combination TLE400 from Global Fund
02 Aug 2019 Q1 FY20 Results: Revenues up by 2 percent
22 July 2019 Laurus Labs' exclusive distribution partner Rising Pharmaceuticals, launches Pregabalin Capsules in US market
12 July 2019 Laurus Labs completed the US FDA inspection of Unit 4 at Visakhapatnam
14 June 2019 USFDA inspection of API facilites Unit 1 & 3 at Visakhapatnam
02 May 2019 FY 19 : Laurus Labs revenues up by 11.5 percent in Q4
26 Mar 2019 FY 19 : Laurus Labs enters into strategic partnership agreement with the Global Fund
11 Mar 2019 FY 19 : Laurus Labs receives two approvals from USFDA
03 Feb 2019 FY 19 : Laurus Labs received tentative approval from USFDA under PEPFAR for TLD FDC
03 Feb 2019 FY 19 : USFDA Approval for TLD Tablets and EIR from USFDA
31 Jan 2019 FY 19 : Laurus Labs Revenue Grew 11% in Q3 FY19
1 Dec 2018 FY 18 : Laurus Labs and Aspen Pharmacare launch an improved triple combination HIV drug in South Africa
1 Nov 2018 FY 18 : Laurus Labs Financial Results Q2 FY2019 Press Release
23 Oct 2018 FY 18 : Press Release Laurus Labs Oct 23 2018
29 Aug 2018 FY 18 : Press Release 29 Aug 2018 - Metformin USFDA Approval
03 Aug 2018 FY 18 : Press Release of Q1 Results 2018-19
10 May 2018 FY 17 : Press Release of Q4 Results 2017-18
1 March 2018 FY 17 : Intimation of completion of USFDA inspection of unit2 with no observations
29 January 2018 FY 17 : Press Release of Q3 9M Results 2017-18
17 January 2018 FY 17 : LAURUS LABS CERTIFIED AS THE “GREAT PLACE TO WORK” IN THE LARGE SIZED ORGANISATIONCATEGORY IN INDIA
9 November 2017 FY 17 : Q2 H1 Results 2017-18 Press Release
10 November 2017 FY 17 : Analyst and Investor Meet Intimation 10-11-2017
15 September 2017 FY 17 : Unit 2 receives EIR from USFDA and completes German Regulatory Authority inspection;
18 August 2017 FY 17 : Laurus Labs completed the USFDA inspection of its API facilities Unit 1 & 3 at Visakhapatnam
10 August 2017 FY 17 : Press Release of Q1 Results 2017-18
5 July 2017 FY 17 : Laurus Labs Credit Rating Improved
18 May 2017 FY 17 : Laurus Labs PAT grows by 40%
9 February 2017 FY 17 : Laurus Labs demonstrates strong Q3 growth In the first quarterly results after successful IPO
Supplier Code of Conduct
Biodiversity & No-deforestation Policy
EHSS Policy
Business Code of Conduct and Ethics Policy
NON-Discrimination Policy
Human Rights Policy
Policy on Grievance Handling
Policy of Prohibition of Child, Adolescent, Forced Labour
POSH Policy
Business Code of Conduct and Ethics Policy
Criteria for determining materiality of events
Data Privacy Policy
Dividend Policy
Remuneration Policy
Archival Policy
Code for Prohibition of Insider Trading
Code of Conduct Policy
Code of Fair Disclosure
Corporate Social Responsibility Policy
Familiarization Programmes for Independent Directors
Policy on Materiality of Subsidiaries
Related Party Transactions Policy
Whistle Blower Policy
Grant of Environmental Clearance (EC) to the proposed Project Activity under the provision of EIA Notification 2006-regarding